Utilization of donor-derived Cell-Free DNA in pediatric kidney transplant recipients: A single center study.
acute rejection
anti-HLA antibody
antibody mediated rejection
pediatric kidney transplantation
Journal
Pediatric transplantation
ISSN: 1399-3046
Titre abrégé: Pediatr Transplant
Pays: Denmark
ID NLM: 9802574
Informations de publication
Date de publication:
07 Aug 2023
07 Aug 2023
Historique:
revised:
02
06
2023
received:
07
04
2023
accepted:
07
07
2023
medline:
8
8
2023
pubmed:
8
8
2023
entrez:
7
8
2023
Statut:
aheadofprint
Résumé
High donor-derived cell-free DNA (dd-cfDNA) levels indicate transplant allograft injury and can identify graft rejection in kidney transplant recipients. Here, we evaluated the use of dd-cfDNA in pediatric kidney transplant rejection monitoring and treatment. Forty-two pediatric kidney transplant patients were enrolled between February 2020 and August 2021. Dd-cfDNA was tested before and after biopsy/rejection treatment. There was a total of 61 allograft biopsies (44 for-cause, 17 surveillance). Graft rejection was found in 35/61 biopsies. Rejection was more common in basiliximab induction compared to rATG (77.1% vs. 22.9%, p = .0121). Median dd-cfDNA was higher in those with rejection (1.2% [0.34-3.12] vs. 0.24% [0.08-0.78], p < .0001). Dd-cfDNA was highest in biopsies with AMR and mixed AMR/TCMR. In addition, dd-cfDNA in basiliximab induction was higher compared to rATG (0.92% [0.27-1.8] vs. 0.26% [0.08-2], p = .0437). Median change in dd-cfDNA after rejection treatment was -0.57% (-1.67 to 0.05). Median time to dd-cfDNA <1% post-rejection treatment was 8.5 days (3.0-19.5). Dd-cfDNA in AMR was higher compared to TCMR or mixed rejection, and levels remained higher in AMR after treatment. In surveillance biopsies, 4/17 had rejection. Median dd-cfDNA was not different in those with versus without rejection (0.48% vs. 0.28%, p = .2342). Those without rejection all had dd-cfDNA <1%. In those with rejection, only one patient had dd-cfDNA >1%, and all had TCMR. Our findings support dd-cfDNA as a useful indicator of graft rejection and response to treatment. Additional studies are needed to determine the role of dd-cfDNA in graft health surveillance.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14582Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Clayton PA, McDonald SP, Russ GR, Chadban SJ. Long-term outcomes after acute rejection in kidney transplant recipients: an ANZDATA analysis. J Am Soc Nephrol. 2019;30(9):1697-1707. doi:10.1681/ASN.2018111101
Redfield RR, Scalea JR, Zens TJ, et al. The mode of sensitization and its influence on allograft outcomes in highly sensitized kidney transplant recipients. Nephrol Dial Transplant. 2016;31(10):1746-1753. doi:10.1093/ndt/gfw099
Josephson MA. Monitoring and managing graft health in the kidney transplant recipient. Clin J Am Soc Nephrol. 2011;6(7):1774-1780. doi:10.2215/CJN.01230211
Kasiske BL, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int. 2010;77(4):299-311. doi:10.1038/ki.2009.377
Filippone EJ, Farber JL. The monitoring of donor-derived cell-free DNA in kidney transplantation. Transplantation. 2021;105(3):509-516. doi:10.1097/TP.0000000000003393
Puliyanda DP, Swinford R, Pizzo H, Garrison J, De Golovine AM, Jordan SC. Donor-derived cell-free DNA (dd-cfDNA) for detection of allograft rejection in pediatric kidney transplants. Pediatr Transplant. 2021;25(2):e13850. doi:10.1111/petr.13850
Bloom RD, Bromberg JS, Poggio ED, et al. Cell-free DNA and active rejection in kidney allografts. J Am Soc Nephrol. 2017;28(7):2221-2232. doi:10.1681/ASN.2016091034
Stites E, Kumar D, Olaitan O, et al. High levels of dd-cfDNA identify patients with TCMR 1A and borderline allograft rejection at elevated risk of graft injury. Am J Transplant. 2020;20(9):2491-2498. doi:10.1111/ajt.15822
Lamarche C, Côté JM, Sénécal L, Cardinal H. Efficacy of acute cellular rejection treatment according to Banff score in kidney transplant recipients: a systematic review. Transplant Direct. 2016;2(12):e115. doi:10.1097/TXD.0000000000000626
Bouatou Y, Viglietti D, Pievani D, et al. Response to treatment and long-term outcomes in kidney transplant recipients with acute T cell-mediated rejection. Am J Transplant. 2019;19(7):1972-1988. doi:10.1111/ajt.15299
Hinojosa RJ, Chaffin K, Gillespie M, Villarreal VH. Donor-derived cell-free DNA may confirm real-time response to treatment of acute rejection in renal transplant recipients. Transplantation. 2019;103(4):e61. doi:10.1097/TP.0000000000002579
Steggerda JA, Pizzo H, Garrison J, et al. Use of a donor-derived cell-free DNA assay to monitor treatment response in pediatric renal transplant recipients with allograft rejection. Pediatr Transplant. 2022;26(4):e14258. doi:10.1111/petr.14258
Haas M, Loupy A, Lefaucheur C, et al. The Banff 2017 kidney meeting report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 2018;18(2):293-307. doi:10.1111/ajt.14625
Dandamudi R, Gu H, Goss CW, Walther L, Dharnidharka VR. Longitudinal evaluation of donor-derived Cellfree DNA in pediatric kidney transplantation. Clin J Am Soc Nephrol. 2022;17(11):1646-1655. doi:10.2215/CJN.03840322
Bu L, Gupta G, Pai A, et al. Clinical outcomes from the assessing donor-derived cell-free DNA monitoring insights of kidney allografts with longitudinal surveillance (ADMIRAL) study. Kidney Int. 2022;101(4):793-803. doi:10.1016/j.kint.2021.11.034
Chang J, Alvarado Verduzco H, Toma K, Sritharan S, Mohan S, Husain SA. Donor-derived cell-free DNA and renal allograft rejection in surveillance biopsies and indication biopsies. Clin Transpl. 2022;36(4):e14561. doi:10.1111/ctr.14561
Gupta G, Moinuddin I, Kamal L, et al. Correlation of donor-derived cell-free DNA with histology and molecular diagnoses of kidney transplant biopsies. Transplantation. 2022;106(5):1061-1070. doi:10.1097/TP.0000000000003838
Kataria A, Kumar D, Gupta G. Donor-derived cell-free DNA in solid-organ transplant diagnostics: indications, limitations, and future directions. Transplantation. 2021;105(6):1203-1211. doi:10.1097/TP.0000000000003651
Oellerich M, Budde K, Osmanodja B, et al. Donor-derived cell-free DNA for personalized immunosuppression in renal transplantation. Ther Drug Monit. 2023;45(1):20-25. doi:10.1097/FTD.0000000000001023
Oellerich M, Sherwood K, Keown P, et al. Liquid biopsies: donor-derived cell-free DNA for the detection of kidney allograft injury. Nat Rev Nephrol. 2021;17(9):591-603. doi:10.1038/s41581-021-00428-0
Wijtvliet VPWM, Plaeke P, Abrams S, et al. Donor-derived cell-free DNA as a biomarker for rejection after kidney transplantation: a systematic review and meta-analysis. Transpl Int. 2020;33(12):1626-1642. doi:10.1111/tri.13753
Anand S, Lopez-Verdugo F, Sanchez-Garcia J, et al. Longitudinal variance of donor-derived cell-free DNA (dd-cfDNA) in stable kidney transplant (KTx) patients are influenced by donor/recipient variables. Clin Transpl. 2021;35(9):e14395. doi:10.1111/ctr.14395
Mehta SG, Chang JH, Alhamad T, et al. Repeat kidney transplant recipients with active rejection have elevated donor-derived cell-free DNA. Am J Transplant. 2019;19(5):1597-1598. doi:10.1111/ajt.15192
Sureshkumar KK, Lyons S, Chopra B. Impact of kidney transplant type and previous transplant on baseline donor-derived cell free DNA. Transpl Int. 2020;33(10):1324-1325. doi:10.1111/tri.13673
Wolf-Doty TK, Mannon RB, Poggio ED, et al. Dynamic response of donor-derived cell-free DNA following treatment of acute rejection in kidney allografts. Kidney360. 2021;2(4):729-736. doi:10.34067/KID.0000042021
Brennan DC, Daller JA, Lake KD, Cibrik D, Del Castillo D; Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med. 2006;355(19):1967-1977. PMID: 17093248. doi:10.1056/NEJMoa060068